Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Asset Writedowns and Impairment (2023 - 2024)

Sangamo Therapeutics (SGMO) has 3 years of Asset Writedowns and Impairment data on record, last reported at -$5.5 million in Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment fell 1965.2% year-over-year to -$5.5 million; the TTM value through Sep 2025 reached -$5.5 million, down 194.91%, while the annual FY2023 figure was $65.5 million, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached -$5.5 million in Q4 2024 per SGMO's latest filing, down from $1.2 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $13.7 million in Q3 2023 and bottomed at -$5.5 million in Q4 2024.